Pivotal misses punish EyePoint and Tenax

The week saw EyePoint and Tenax lose more than half their value on Phase III readouts in wet age-related macular degeneration and pulmonary hypertension, respectively.

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced Monday that Duravyu, its vorolanib intravitreal insert, failed to meet the primary endpoint of non-inferiority to standard-of-care Eylea aflibercept in the Phase III LUGANO study in wet age-related macular degeneration...